Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 1
2014 4
2015 1
2016 2
2017 1
2018 3
2019 5
2020 2
2021 5
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators. Eng C, et al. Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Lancet Oncol. 2019. PMID: 31003911 Clinical Trial.
Another gastrointestinal lesion amendable for ablation.
Jorissen C, Vertessen A, Bossuyt P, Cuyle PJ, Bronswijk M. Jorissen C, et al. Among authors: cuyle pj. Acta Gastroenterol Belg. 2022 Jan-Mar;85(1):113. doi: 10.51821/85.1.9277. Acta Gastroenterol Belg. 2022. PMID: 35305005 Free article.
Minimally invasive treatment of a bulging appendiceal orifice.
Jorissen C, Lansink F, Cuyle PJ, Bronswijk M. Jorissen C, et al. Among authors: cuyle pj. Acta Gastroenterol Belg. 2021 Jul-Sep;84(3):522. doi: 10.51821/84.2.020. Acta Gastroenterol Belg. 2021. PMID: 34599582 Free article. No abstract available.
Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T. Perkhofer L, et al. Among authors: cuyle pj. Cancers (Basel). 2021 Aug 24;13(17):4259. doi: 10.3390/cancers13174259. Cancers (Basel). 2021. PMID: 34503069 Free PMC article.
Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study.
Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Martinelli E, et al. Among authors: cuyle pj. ESMO Open. 2022 Dec;7(6):100603. doi: 10.1016/j.esmoop.2022.100603. Epub 2022 Nov 8. ESMO Open. 2022. PMID: 36368253 Free PMC article.
27 results